Roche acquires Inflazome to gain control over inflammatory treatments

By Nikita Chaurasia  | Date: 2020-09-22

Roche acquires Inflazome to gain control over inflammatory treatments

In a recent turn of events, Swiss healthcare giant, F. Hoffmann-La Roche AG has reportedly acquired an Irish biotech firm Inflazome Ltd. for approximately USD 451 million (€380 million).

As per the agreement, Roche will acquire complete rights to Inflazome’s portfolio of oral NLRP3 inflammasome inhibitors, which are currently being developed for treating conditions such as Parkinson’s and other diseases, sources claimed.

Since its inception in 2016, Inflazome has been gaining worldwide recognition owing to its expertise in inflammasome inhibitors.  The firm is currently developing an oral NLRP3 inflammasome inhibitor in order to meet the unmet demands for various inflammatory diseases. In fact, the company claims the inhibitor has already completed Phase 1 human trails as well as various early-stage programmes.

Inflazome is also developing drugs which targets inflammasomes associated with arthritis, asthma, Alzheimer’s, Parkinson’s, and bowel disease as well as other chronic inflammatory conditions, cited sources with relevant information.

Matt Cooper, CEO at Inflazome was reported saying that the company is thrilled to enter a joint venture agreement with one of the prominent pharmaceutical giant Roche. He added that the acquisition will allow Inflazome to quickly and effectively develop its products in order to aid patients with debilitating diseases.

It is to be noted that earlier in July, Roche and its subsidiary Genentech Inc. entered a joint venture agreement with UCB, a Belgian company to produce and commercialize an antibody drug UCB0107 for treating Alzheimer’s disease

Several other pharmaceutical companies are also working on similar drug developments. In fact, IFM Therapeutics sold its subsidiaries with NLRP3 assets to Novartis International AG and Bristol Myers Squibb (BMS).

Source credits –

https://www.fiercebiotech.com/biotech/roche-pays-eu380m-for-nlrp3-biotech-inflazome-claiming-a-leading-position-hot-field

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

By Nikita Chaurasia

Swiftly Systems has reportedly achieved unicorn status, securing in funding through a Series C round. The prominent BRV Capital Management led this funding initiative. According to the earlier reports, Swiftly was adopted by hundreds of consumer b...

Rainforest nations unify to demand cash for climate & biodiversity preservation

Rainforest nations unify to demand cash for climate & biodiversity preservation

By Nikita Chaurasia

As per the reports, twelve nations with rainforests united to establish a collective initiative aiming to address climate change and safeguard biodiversity at summit held in Brazil. The declaration, titled "United for Our Forests," emerged ...

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

By Nikita Chaurasia

Meta Platforms has recently introduced Llama 2, an artificial intelligence large language model, for commercial use in collaboration with major cloud providers like Microsoft. Instead of charging for access or usage, Meta aims to share the model with...

Moderna signs agreement to explore mRNA medicines in China

Moderna signs agreement to explore mRNA medicines in China

By Nikita Chaurasia

Moderna Inc, a leading vaccine manufacturer, reportedly announced on Wednesday that it has entered into a memorandum of understanding (MoU) and a land collaboration agreement aimed at exploring opportunities for researching, developing, and producing...

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

By Nikita Chaurasia

The American footwear design & manufacturing company, Nike and Epic Games, the creators of the popular online game Fortnite, have joined forces in an exciting new collaboration. The partnership aims to bring about a groundbreaking change in the d...